Form4insider filings, from the source

SEC Form 3 · accession 0000315066-17-002684

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
FMR LLC
10% Owner · Other
Period of report
Aug 11, 2017
Accepted (ET)
Aug 18, 2017 · 10:15 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2holding———304,343IF-Prime Capital Partners Healthcare Fund III LP
Common StockF1,F3holding———15,665IF-Prime Capital Partners Healthcare Advisors Fund III LP
Common StockF1,F4holding———6,309IF-Prime Inc
Common StockF1,F5holding———300IFIMM, LLC

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: In addition to the securities shown in Table I, FMR Co., Inc., FIAM LLC, and SAI, each of which is an indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered under the Investment Advisers Act of 1940, and FIAMTC, an indirect, wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, are the beneficial owners of 2,787,840 shares, or 9.294%, of Common Stock of Aclaris Therapeutics, Inc., as a result of acting as investment advisers to various investment companies registered under the Investment Company Act of 1940 and other funds and accounts. FMR LLC and Abigail P. Johnson have no pecuniary interest in these 2,787,840 shares of Common Stock. Remark 3: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.